Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

4SC Discovery, Crelux and Ribological Launch Collaboration

Published: Tuesday, July 17, 2012
Last Updated: Tuesday, July 17, 2012
Bookmark and Share
Collaboration for the discovery and optimization of new anti-cancer drugs.

4SC AG has announced that its subsidiary 4SC Discovery GmbH, which specializes in the discovery and early-stage research of novel therapeutic compounds, has agreed a research collaboration with Ribological GmbH, Mainz, in the area of compound screening.

The aim of the research project is to identify and optimize new and more effective anti-cancer compounds.

4SC Discovery and Crelux GmbH, its strategic partner for services in the field of biopharmaceutical early-stage research, have been commissioned by Ribological to implement a hit finding programme to identify and optimize potential new small molecule compounds that are expected to have a synergistic effect with the RNA molecules used by Ribological in cancer immunotherapy.

Ribological intends to carry out preclinical testing of the compounds and, if successful, develop these further in clinical trials in combination with its RNA-based drugs.

In detail, 4SC Discovery is using its patented IT-aided in silico screening process to perform calculations of the properties of several million substances with the goal of identifying the best possible drug candidates.

This is intended to accelerate the development process for early-stage compound research and achieve greater cost efficiency than conventional approaches.

Crelux, 4SC Discovery's research partner that specializes in research services in the field of proteins, especially protein production and crystallization, is performing the associated molecular-biological tests for optimizing the compounds in INTRACT-MST assays.

The partnership will generate revenue that could reach the low six-figure euro range for each 4SC Discovery and Crelux.

Dr. Daniel Vitt, Managing Director of 4SC Discovery GmbH and Chief Scientific Officer at 4SC AG, comments: 'We are delighted to have secured Ribological as a cooperation partner for our drug discovery activities - a company with a strong research track record and a highly innovative approach in cancer medicine. This is also the first major joint project that we have launched as part of our new strategic i2c (idea to candidate) cooperation with our partner Crelux. As service providers and cooperation partners for biotech and pharma companies, 4SC Discovery and Crelux together can cover both the entire value chain from the idea for a product to the preclinical drug development candidate and also supplement it as needed.'

Prof. Dr. Ugur Sahin, Managing Director of Ribological GmbH, comments: 'In 4SC Discovery GmbH we have won an expert and, simultaneously, an exceedingly pleasant cooperation partner for small molecule compound screening. We expect this to be a high-level synergistic collaboration.'

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

4SC Strengthens Patent Protection for Lead Cancer Compound Resminostat
US patent for medical use in cancer and Canadian composition of matter patent granted.
Wednesday, July 01, 2015
BEYOND RESEARCH Initiative of 4SC Discovery and CRELUX Reaches First Milestone
Compounds for inhibiting oxygen radicals and associated signalling pathways optimized for developing innovative therapies for degenerative diseases.
Tuesday, January 13, 2015
4SC Discovery Receives EU Grant Worth EUR 450,000
Three-year research collaboration with the Medical Clinic of the University of Munich includes a project for identification and optimization of new compounds against a novel epigenetic target molecule.
Thursday, April 17, 2014
4SC Announces Financial Results for a Successful Year 2012
Consolidated results considerably improved due to rising revenue and reduced costs.
Tuesday, March 26, 2013
4SC AG Further Strengthens Supervisory Board
Appointment of Dr Irina Antonijevic and Mr Klaus Kühn.
Monday, December 31, 2012
4SC's Successful Development Continues in Third Quarter of 2012
Consolidated financial results improved in third quarter and first nine months.
Friday, November 09, 2012
4SC Announces Financial Results for the First Quarter of 2012
Company has made a successful start to 2012.
Monday, October 22, 2012
4SC Receives Milestone Payment from Research Collaboration with SKK
4SC had contributed its know-how in the field of medicinal chemistry to investigate new classes of substances for the potential therapy of metabolic diseases.
Monday, October 15, 2012
4SC's Vidofludimus Shows Preclinical Evidence in a Kidney Transplantation Model
New preclinical data published in peer-reviewed article in Transplantation.
Tuesday, June 19, 2012
4SC AG Announces Election of Dr Thomas Werner to Chairman of the Supervisory Board
Company also elected Dr Manfred Rüdiger as its new deputy chairman.
Thursday, June 14, 2012
4SC's Partner Yakult Honsha Starts Clinical Development with Cancer Compound Resminostat in Japan
The Phase I study will assess safety of resminostat in Japanese patients, which is a prerequisite of the drug's further late-stage clinical development in Japan.
Monday, May 21, 2012
4SC Discovery and CRELUX Enter into a Strategic Alliance
Strategic partnership for integrated drug discovery services.
Monday, April 23, 2012
4SC to Present at Two Upcoming Investor Conferences
Future leaders in the Biotech Industry conference, 20 April 2012 in New York.
Tuesday, April 17, 2012
Henkel and 4SC Discovery Start Research Collaboration in Compound Screening
Aim is to identify new and more effective laundry detergent ingredients.
Monday, April 09, 2012
4SC’s Resminostat Receives Positive Opinion for Orphan Medicinal Product Designation
European Medicines Agency recommend resminostat as orphan medicinal product for the treatment of Hodgkin’s Lymphoma.
Friday, October 14, 2011
Scientific News
Inroads Against Leukemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Diabetes Drugs May Actually Release Sugar Into the Blood
A family of drugs used to treat Type 2 diabetes could promote the release of sugars into the blood - something the drugs are supposed to prevent, Cambridge scientists have claimed.
Nanoparticles Can Make Medicines More Effective
Nanoparticles wrapped inside human platelet membranes serve as new vehicles for targeted drug delivery.
A Better Class of Cancer Drugs
An SDSU chemist has developed a technique to identify potential cancer drugs that are less likely to produce side effects.
Preventing Crystallization to Improve Drug Efficiency
Esther Amstad and an international team of researchers have developed a method to increase the solubility of poorly soluble substances, such as many of the newly developed drugs.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos